|
Mr. Brand brings more than 30 years of global pharmaceutical experience in product development, acquisitions, marketing and operational management with GlaxoSmithKline, its predecessor companies, and most recently as President and CEO of Cardiokine.
Mr. Brand joined GSK International from the Canadian operation in 1983 in the post of Vice President, Cardiovascular/Gastrointestinal Marketing. Over the next 7 years, he held VP positions in marketing, business development, and regional operations in Asia, Europe and Latin America.
In 1990, Mr. Brand joined the GSK US organization as Business Unit Head for Gastrointestinal and Central Nervous System Products, where he led the launch activities for Paxil and Kytril. In 1994, as Vice President of New Product Planning, he was responsible for the pre-launch commercial development plans for Coreg, Hycamptin, Requip and numerous in-licensing, co-promotion, co-development partnerships. From 1997 through 2003, Mr Brand headed up the anti-infective, metabolic and cardiovascular business units that launched Requip, Avandia and Avandia extensions, and development of Augmentin ES/XR.
From 2004 to September 2007, Mr. Brand served as President and CEO of Cardiokine, a specialty pharmaceutical company developing lixivaptan. Over this period, Mr. Brand built a first class management and development team, successfully closed a $50 million Series B financing and completed a global lixivaptan co-development, co-marketing agreement with Biogen Idec.
Mr. Brand holds a Bachelor of Commerce degree from Concordia University in Montreal, Canada. | 